Journal of Clinical Oncology
Articles in this Issue
DIPCAN, a multidimensional approach to precision oncology: Harnessing genomic, clinical, pathological and radiographic data to advance personalized cancer treatment.
TPS1656 Background: Advances in big data analytics and artificial intelligence (AI) are enabling novel approaches to patient classification in oncology. W...
Impact of human immunodeficiency virus on hepatocellular carcinoma outcomes: A National Inpatient Sample.
e16334 Background: Human Immunodeficiency Virus (HIV) infection continues to pose significant global health challenges, affecting millions of individuals....
Impact of interruptions in chemotherapy on survival for patients with metastatic or recurrent cervical cancer.
e17522 Background: Chemotherapy interruptions in metastatic cervical cancer are not an infrequent event. Interruptions in treatment of solid tumors have b...
Familial lung cancer: A thirteen-year prospective analysis of participants with germline EGFR T790M pathologic variant.
10617 Background: Lung cancer in never-smokers is the eighth leading cause of cancer-related mortality in the United States. Familial lung cancer, a rare...
Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.
5555 Background: Platinum-resistant/refractory ovarian cancer presents a significant therapeutic challenge and despite several attempts, immunotherapies h...
Quantification of tumor subregions in glioblastoma multiforme: A volumetric analysis.
e14015 Background: In the last 30 years only one drug (temozolomide) has been shown to provide a significant improvement in survival of patients with newl...
Development and prospective validation of a novel cfDNA-based diagnostic model for the early detection of pancreatic cancer.
4191 Background: Pancreatic cancer (PC) is one of the most lethal malignancies, with a 5-year survival rate below 10%, primarily due to late-stage diagnos...
Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer.
3580 Background: Trifluridine/tipiracil (FTD-TPI; Lonsurf) is an oral antineoplastic agent approved for 3 rd -line use in combinat...
Real-world prospective study on compassionate and off-label novel anticancer therapies in children, adolescents, and young adults: The SACHA-INTERNATIONAL ITCC study.
e22016 Background: Novel anticancer therapies are regularly prescribed outside their marketing authorization or through compassionate use programs to chil...
Breaking barriers for patients with stage IV non-small cell lung cancer with brain metastases: Insight into the impact of immunotherapy on survival and survival disparities.
8545 Background: Brain metastases (BM) correlate with poor prognosis, occurring in 10% of non-small cell lung cancer (NSCLC) patients (pts) at diagnosis a...
Economic modelling to inform pricing for LMICs of immune checkpoint inhibitors in advanced PD-L1-high non-small cell lung cancer.
1518 Background: Lung cancer is the most common cancer and cause of cancer death, encompassing for 16.8% of all cancer-related deaths worldwide. Anti-PD(L...
Exploratory biomarker analysis for progression during adaptive androgen deprivation therapy for metastatic castration sensitive prostate cancer.
e17095 Background: When cure is not feasible, adaptive therapy can provide better control of metastatic cancer by delaying the evolution of treatment resi...
Decoding tumour bacterial ecosystems: Topological data analysis of bacterial association with immunogenicity.
10563 Background: The tumour microbiome is increasingly recognised as a key contributor to cancer progression and clinical outcomes, as highlighted in rec...
DM005: An anti-EGFR/c-MET bispecific antibody-drug conjugate for advanced solid tumors.
e15010 Background: Bispecific ADCs (BsADCs) enhance efficacy, reduce toxicity, and overcome drug resistance by increasing...
Chemoimmunotherapy in advanced biliary tract cancers: A meta-analysis of clinical outcomes.
e16257 Background: Biliary tract cancers (BTCs)—encompassing tumors of the bile ducts, gallbladder, or ampulla of Vater—are notoriously hard to manage, es...
Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.
e21519 Background: Uveal melanoma has a poor prognosis once liver metastases occur. Melphalan/Hepatic Delivery System (Melphalan/HDS) is a drug/device com...
Improving patient outcomes by assessing unmet social needs: A preliminary study in a urologic oncology clinic.
e23151 Background: Social determinants of health (SDOH) and Health-related social needs (HRSN) play a key role in care outcomes. Yet comprehensive assessm...
Feasibility of circulating tumor DNA-based minimal residual disease (ctDNA-MRD)-guided adjuvant chemotherapy in patients with stage II-III gastric cancer (GC): An adaptive trial (MRD-GATE).
4061 Background: Although adjuvant chemotherapy (ACT) is the standard treatment for stage II-III GC, this strategy lacks precision treatment options, and...
Trends in lung cancer incidence and treatment across the US 2019-2023.
e23309 Background: We analyzed patterns in incidence, treatment, and patient characteristics including time to treatment, age, sex, race, stage, histologi...
Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: A retrospective study.
8023 Background: Consolidative chest radiotherapy (XRT) after chemoimmunotherapy may provide benefits in extensive-stage small cell lung cancer (ES-SCLC)...
Identifying key predictors of MSI/MMR status in colorectal cancer: Insights from a real-world clinical dataset.
e15718 Background: Microsatellite instability (MSI) and mismatch repair (MMR) testing is critical for guiding therapeutic decisions in colorectal cancer (...
Evaluating the outcome of cardiovascular risk factors in breast cancer patients.
586 Background: Breast cancer patients are at increased risk of cardiovascular disease due to factors such as treatment-related toxicity and shared comorb...
Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
TPS4230 Background: Patients with previously treated metastatic PDAC have significant need for treatments with improved efficacy and tolerability. RAS is...
Real-world side effects of targeted therapies: High-throughput association studies leveraging the CancerLinq Discovery lung cancer database.
1553 Background: Targeted therapies have unique side effect profiles distinct from other cancer drugs. Challenges of collecting generalizable toxicity dat...
Assessing the impact of scalp cooling in patients receiving trastuzumab deruxtecan for metastatic breast cancer.
1095 Background: Outcomes for patients (pts) with metastatic breast cancer (MBC) have improved with novel antibody drug conjugates like trastuzumab deruxt...